Daniel Paul Regan, Chief Commercial Officer at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 20,000 shares at $431.34 ($8.7M) on 2014-03-05, disclosed to the SEC on 2014-03-07.
Scheduled sale ($8.7M) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $426.06 | 500 | $213K | 2.5% |
| 2 | $427.05 | 500 | $214K | 2.5% |
| 3 | $428.51 | 700 | $300K | 3.5% |
| 4 | $429.95 | 361 | $155K | 1.8% |
| 5 | $431.34 | 339 | $146K | 1.7% |
| 6 | $432.84 | 1,724 |
| $746K |
| 8.6% |
| 7 | $433.47 | 7,027 | $3.0M | 35.0% |
| 8 | $434.57 | 1,949 | $847K | 9.7% |
| 9 | $435.70 | 1,140 | $497K | 5.7% |
| 10 | $436.77 | 1,960 | $856K | 9.8% |
| 11 | $438.45 | 898 | $394K | 4.5% |
| 12 | $439.94 | 502 | $221K | 2.5% |
| 13 | $440.63 | 812 | $358K | 4.1% |
| 14 | $441.59 | 1,288 | $569K | 6.5% |
| 15 | $442.49 | 300 | $133K | 1.5% |
| Total | $434.69 avg | 20,000 | $8.7M | 100% |
| Filing → |
| ICPT | SELL | 2014-08-15 | $2.6M | — | Filing → |
| ICPT | SELL | 2014-07-08 | $250 | — | Filing → |